For those tumors not exquisitely dependent on or sensitive to the depletion of MCL1, e.g. those with some reliance upon other BCL2 family members, including some AML cell lines reported here (HEL, THP-1, PL21), a combination strategy has worked very well in preclinical experiments. The gene discussed is MCL1; the disease is acute myeloid leukemia.